文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

安非他酮与丁丙诺啡减少甲基苯丙胺渴求的随机临床试验

A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
PubMed 文献 · Trials · 2019-07-30

该研究将65名符合DSM-IV-TR甲基苯丙胺依赖及戒断标准的男性随机分为两组,分别每日接受300 mg安非他酮或8 mg丁丙诺啡治疗2周。结果显示两药均能减少渴求,丁丙诺啡组渴求减少显著优于安非他酮组(P=0.011),作者推荐每日8 mg丁丙诺啡用于治疗甲基苯丙胺戒断渴求,但指出渴求随时间自然下降,仅丁丙诺啡确定有效。

要点

  • 丁丙诺啡组渴求减少显著优于安非他酮组(P=0.011)。
  • 作者推荐每日8 mg丁丙诺啡用于治疗甲基苯丙胺戒断渴求。
  • 作者指出渴求随时间自然下降,仅丁丙诺啡确定降低渴求。

核心结论

  • 结果支持丁丙诺啡和安非他酮治疗甲基苯丙胺戒断渴求的安全性和有效性。
  • 作者推荐每日8 mg丁丙诺啡用于治疗甲基苯丙胺戒断渴求。
  • 作者指出渴求随时间自然下降,仅丁丙诺啡确定降低渴求。

研究设计与样本

  • 随机临床试验,65名符合DSM-IV-TR甲基苯丙胺依赖及戒断标准的男性随机分为两组。
  • 35名(53.8%)接受每日8 mg丁丙诺啡,30名(46.2%)接受每日300 mg安非他酮,治疗2周。
  • 采用甲基苯丙胺渴求评分、访谈和阴性尿药检测进行评估。

主要发现

  • 两组在年龄、教育、甲基苯丙胺依赖时长、婚姻状况、就业和收入方面无统计学显著差异。
  • 丁丙诺啡组平均年龄32.8岁(标准差=7.26,范围22至59),安非他酮组平均年龄32.21岁(标准差=8.45,范围17至51)。
  • 全部65名患者完成2周研究。
  • 丁丙诺啡组渴求减少显著多于安非他酮组(P=0.011)。
  • 检测到显著的天主效应(P<0.001)和组主效应(P=0.011),组别与天数的交互作用不显著(P>0.05)。

临床怎么用

  • 作者推荐每日8 mg丁丙诺啡用于治疗甲基苯丙胺戒断渴求。
  • 作者指出渴求随时间自然下降,仅丁丙诺啡确定降低渴求。

局限性

  • 作者指出渴求随时间自然下降,因此结论可能并非安非他酮和丁丙诺啡均降低渴求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval. METHOD: Sixty-five methamphetamine-dependent men who met the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) criteria for methamphetamine dependence and withdrawal were randomly divided into two groups. Subjects randomly received 300 mg of bupropion or 8 mg of buprenorphine per day in a psychiatric ward. Of the 65 subjects, 35 (53.8%) received buprenorphine and 30 (46.2%) received bupropion. The subjects were assessed by using methamphetamine craving score, interview, and negative urine drug test. FINDINGS: There were no statistically significant differences between the two groups in regard to age, education, duration of methamphetamine dependency, marital status, employment, and income. The mean ages were 32.8 years (standard deviation (SD) = 7.26, range = 22 to 59) for the buprenorphine group and 32.21 years (SD = 8.45, range = 17 to 51) for the bupropion group. All 65 patients completed the 2-week study. Both medications were effective in the reduction of methamphetamine cravings. Reduction of craving in the buprenorphine group was significantly more than the bupropion group (P = 0.011). Overall, a significant main effect of day (P <0.001) and group (P = 0.011) and a non-significant group-by-day interaction (P >0.05) were detected. CONCLUSIONS: The results support the safety and effectiveness of buprenorphine and bupropion in the treatment of methamphetamine withdrawal craving. Administration of 8 mg of buprenorphine per day can be recommended for the treatment of methamphetamine withdrawal cravings. We should note that it is to be expected that craving decreases over time without any medication. So the conclusion may not be that bupropion and buprenorphine both lower the craving. As the buprenorphine is superior to bupropion, only buprenorphine does so for sure. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT) registration number: IRCT2015010320540N1 . Date registered: April 10, 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ahmadi J, Sahraian A, Biuseh M, et al. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving. Trials. 2019. PMID: 31362784. doi:10.1186/s13063-019-3554-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。